abstract: A novel in-situ electrochemical oxidation method was applied to the degradation of wastewater containing @entity3 . Under @entity0 sparging, the strong oxidant, @entity2 , could be in-situ generated through the reduction of @entity0 on the surface of the cathode. The removal rate of @entity3 could be increased 149% when @entity0 was induced in the electrochemical cell. The promotion factor was estimated to be about 82.63% according to the pseudo-first-order reaction rate constant (min(-1)). Important operating parameters such as current density, sparged @entity0 rate investigated. Higher sparged @entity0 rate could improve the degradation of @entity3 . To make full use of @entity0 , however, sparged @entity0 rate of 0.05 m(3)/h was adopted in this work. Oxidation-reduction potential could remarkably affect the generation of @entity1 . It was found that the removal rate of @entity3 was not in direct proportion to the applied current density. The optimum current density was 3.5 mA/cm(2) when initial @entity3 concentration was 100 mg/L and sparged @entity0 rate was 0.05 m(3)/h.

title: Degradation of XXXX by in-situ electrochemically generated oxidant.

answer: @entity3


abstract: BACKGROUND: @entity8 ( @entity8 ) rarely occurs as the first evidence of a @entity2 . In such cases cytology of the cerebrospinal fluid is crucial to the diagnosis. The most frequent primary MCs are lung and @entity0 . @entity8 from a @entity7 is uncommon. CASE: A 58-year-old @entity1 presented with paroxysmal headaches, @entity4 and @entity6 . Analysis of the cerebrospinal fluid revealed @entity3 cells and a low protein concentration. Only postmortem examination discovered @entity5 to be the source of the @entity2 cells. CONCLUSION: A case with the onset of @entity8 secondary to rare mucinous @entity5 is presented. Cytology of the cerebrospinal fluid was the only examination that uncovered @entity2 . Nine similar cases were found in the literature. Low cerebrospinal fluid protein seems to be of diagnostic value.

title: XXXX cells in cerebrospinal fluid as the first manifestation of a @entity2 . A case report.

answer: @entity7


abstract: BACKGROUND: @entity8 ( @entity8 ) rarely occurs as the first evidence of a @entity2 . In such cases cytology of the cerebrospinal fluid is crucial to the diagnosis. The most frequent primary MCs are lung and @entity0 . @entity8 from a @entity7 is uncommon. CASE: A 58-year-old @entity1 presented with paroxysmal headaches, @entity4 and @entity6 . Analysis of the cerebrospinal fluid revealed @entity3 cells and a low protein concentration. Only postmortem examination discovered @entity5 to be the source of the @entity2 cells. CONCLUSION: A case with the onset of @entity8 secondary to rare mucinous @entity5 is presented. Cytology of the cerebrospinal fluid was the only examination that uncovered @entity2 . Nine similar cases were found in the literature. Low cerebrospinal fluid protein seems to be of diagnostic value.

title: @entity7 cells in cerebrospinal fluid as the first manifestation of a XXXX . A case report.

answer: @entity2


abstract: INTRODUCTION: Prophylactic campaign against @entity0 wide spread by Regional Center of Oncology made significant influx of @entity1 coming to our place and presenting less advanced stages of the mentioned disease. AIM: The aim of this work was estimate of BCT treatment standard for invasivum @entity3 and preinvasivunm @entity0 treatment standard which was adapted in RCO. MATERIALS AND METHOD: @entity1 presenting unifocal @entity2 smaller than 2 cm, stage No, where the minimal margin of more than 1 cm was possible to perform, were qualified to BCT. Minimal surgical border during tumorectomy was 1 cm. We were excluded @entity1 with @entity4 lobulare and @entity4 mucinosum. During qualification to DCIS treatment standard first we must exclusion multifocalis cases based on Anderson classification and Falun consens. In the other cases we based on Van Nuys Prognostic Index (VNPI) considering the @entity1 's age. We have 3 forms of treatment: simplex mastectomy, tumorectomy and tumorectomy with RTG-therapy. To BCT standard were qualified 52 @entity1 . Schematically was attended 45 @entity1 . We had 5 @entity1 which was attended based on preinvasivum @entity0 treatment standard. RESULTS: The size of @entity0 at the @entity1 which was attended based on BCT standard was 0,5-2 cm. 3 @entity1 was disqualified from BCT because we found second @entity0 focus in histopathological material. We must widen surgical @entity5 in 5 cases. Among 5 @entity1 with preinvasivum @entity3 was 3 simplex mastectomy and 2 cases tumorectomy with RTG-therapy. CONCLUSIONS: In our opinion BCT treatment standard and breast preinvasivum @entity3 treatment standard should be using only in high specialty oncological center. It is a guaranty of right qualification and treatment for @entity0 @entity1 .

title: [Evaluation of breast conserving therapy (BCT) standards for invasive and preinvasive XXXX adapted in RCO in Bydgoszcz].

answer: @entity0


abstract: The McMaster Health Utilities Indexes @entity1 (HUI2) and 3 (HUI3) are multiattribute health classification systems, for which multiattribute preference functions have been developed in Canada. They provide a comprehensive instrument for use in economic evaluations and population health survey studies. This paper reports on the first results on the adaptation of the HUI2 and HUI3 systems cross-culturally and the assessment of the validity and reliability of the French self-report questionnaire in different @entity0 populations. The cross-cultural adaptation included translation, backtranslations, an expert consensus meeting and pre-test with a few @entity0 and healthy subjects in order to produce a conceptually equivalent French version of the 15 question self-report questionnaire and the HUI2 and HUI3 classification systems. Different groups of @entity0 attending specialized clinics (n = 709) completed the questionnaire and another generic questionnaire (the Sickness Impact Profile (SIP)) for validity assessment. Physicians and @entity0 were also asked for a global subjective assessment of the @entity0 's health status. The French questionnaire was well received by the @entity0 . The criterion and convergent validities of both classification systems (correlations with the @entity0 ' and physicians' assessments and with the responses to the SIP questionnaire) were satisfactory. The internal consistency was acceptable too (Cronbach's alpha = 0.81), as was the 3 day test-retest reproducibility. These first results authorize careful use of the 15 question self-report questionnaire in French. An assessment of the multiattribute preference function for the HUI3 system in France will be the study's next objective.

title: French cross-cultural adaptation of the Health Utilities Indexes XXXX (HUI2) and 3 (HUI3) classification systems. Clinical and Economic Working Groups.

answer: @entity1


abstract: To receive an overview of the presently used methods for the operative treatment of @entity2 of the proximal humerus a prospective controlled multicenter study was arranged. 146 @entity2 from 145 @entity0 (76 females, 69 @entity0 ) were assessed, documented with the AO standard sheets and radiographs and with a one year follow-up examination. Each of the nine clinics used his own treatment scheme. They applied: K-wires (27%) for adaptation and for intramedullary fixation; tension band wires (16%) or sutures (11%) alone or in combination with K-wires; osteosynthesis with screws alone (7%) or with plates (22%). In 17% the humeral-head was acutely replaced with a prosthesis. 11 @entity2 (8%) had to be reoperated because of instability or loss of fixation. 109 @entity0 were available for clinical review, one @entity0 could be questioned by letter and six @entity0 had died after one year (follow-up 80%). In 38% of @entity0 full limb function was restored, @entity1 persisted in 45% and 17% remained severely handicapped. 96 @entity2 (89%) were consolidated, 30% with a deformity. 35% of @entity0 still were unable to work full time. The treatment of @entity2 of the proximal humerus is generally difficult. More over the various operative methods and problematic fracture classification make a differentiate statistical analysis impossible. Still many questions remain. For answers a new trial is mandatory. For this future series fixed guidelines for indications and operative treatment modalities are required to allow a meaningful comparison of results and a scoring system for evaluation of functional outcome is necessary.

title: [Surgical treatment of proximal humerus XXXX --international multicenter study].

answer: @entity2


abstract: @entity2 are locally acting hormones that have remarkable variety of physiological functions. They are rapidly synthesized in several types of vertebrate cells as oxygenated metabolites of @entity0 in response to various stimuli. In many insect species they are biosynthesized in fat body and hemocytes mainly in response to @entity1 . In the present study, we administered synthetic analog of @entity4 , the most prominent of the @entity2 to the 48 h old fifth instar @entity5 , @entity5 L. at a single dose of 4 microg per larva to study its effects on the larval growth pattern and silk synthesis. The possible role of PGF2alpha at altering the quantum of silk synthesis by controlling the silk gene expression was also studied. The genomic DNA was isolated from the posterior silk gland on Days 5 and 7 of the fifth instar from the @entity3 treated and the control larvae and were random amplified with arbitrary primers. The result presented notable variation in the amplified product suggesting the participation of PGF2alpha in the silk biosynthesis controlling the silk gene expression. The feeding period of treated larvae was unaffected while the cocoon characters exhibited considerable improvement. The filament traits also were improved notably in the treated larvae. The participation of PGF2alpha analog in the silk biosynthetic process with its physiological and molecular implications are discussed.

title: Exogenous @entity4 as a mediator in the regulation of XXXX growth and silk gland genome.

answer: @entity5


abstract: @entity2 are locally acting hormones that have remarkable variety of physiological functions. They are rapidly synthesized in several types of vertebrate cells as oxygenated metabolites of @entity0 in response to various stimuli. In many insect species they are biosynthesized in fat body and hemocytes mainly in response to @entity1 . In the present study, we administered synthetic analog of @entity4 , the most prominent of the @entity2 to the 48 h old fifth instar @entity5 , @entity5 L. at a single dose of 4 microg per larva to study its effects on the larval growth pattern and silk synthesis. The possible role of PGF2alpha at altering the quantum of silk synthesis by controlling the silk gene expression was also studied. The genomic DNA was isolated from the posterior silk gland on Days 5 and 7 of the fifth instar from the @entity3 treated and the control larvae and were random amplified with arbitrary primers. The result presented notable variation in the amplified product suggesting the participation of PGF2alpha in the silk biosynthesis controlling the silk gene expression. The feeding period of treated larvae was unaffected while the cocoon characters exhibited considerable improvement. The filament traits also were improved notably in the treated larvae. The participation of PGF2alpha analog in the silk biosynthetic process with its physiological and molecular implications are discussed.

title: Exogenous XXXX as a mediator in the regulation of @entity5 growth and silk gland genome.

answer: @entity4


abstract: OBJECTIVE: To discuss the methods and effects of serial therapies oriented by surgery in the treatment of primary large @entity2 . METHODS: From January 1993 to June 1999, 191 @entity0 with large @entity2 were treated surgically. The size of @entity1 varied from 5.2 to 19.7 cm (mean 9.4 cm). Several types of liver resections were made in 121 @entity0 and as a supplement, cryosurgery was carried out for the remaining 70 @entity0 . Importable drug delivery system was instituted intraoperatively. Transcatheter @entity6 ( @entity9 30-60 mg, E-ADM 20-40 mg, CDDP 40-80 mg, @entity5 10-20 mg, iodin oil 5-30 ml), percutaneous @entity4 injection, bioimmunotherapy and traditional Chinese medicine were used pre- and post-operatively. CT angiography and CT during arterial portography were used to find satellite nodules. Early stage recurrences were predicted by AFPmRNA in peripheral blood. @entity0 -Pugh's classification plus branch chain @entity3 /aromatic @entity3 ratio ( @entity10 /AAA) was adopted in evaluating pre-operative liver functions. RESULTS: Marked results were observed after serial treatments oriented by surgery. The 1-, 3- and 5-year survival rates in resection group were 75.8%, 45.6% and 30.4%, respectively. The 1- and 3-year survival rates in cryosurgery group were 63.2% and 37.0%. The operative mortality was 1.57%. Recurrence rates were 69.2% in AFPmRNA positive group and 33.3% in AFPmRNA negative group (P<0.05). The @entity10 / @entity8 ratio was lower than 1.5 in two @entity0 who died of @entity7 after resection. CONCLUSIONS: Serial treatments with surgery as the chief modality gives satisfactory results in @entity0 with large primary @entity2 . This regimen should be regarded as a main strategy to deal with large @entity2 . AFPmRNA in the peripheral blood, signifying a recurrence, may become a new clinical parameter. The @entity10 /AAA ratio plus @entity0 -Pugh's classification is able to evaluate more accurately liver function reserve before surgery.

title: Serial therapies oriented by surgery for large primary XXXX .

answer: @entity2


abstract: BACKGROUND: Early pathogenetic events of @entity3 may be overlooked in @entity0 with serologic markers of @entity2 and normal intestinal mucosa by both conventional histology and immunohistochemistry. AIMS: To investigate if a submicroscopical damage of the absorptive cell surface was associated with developing @entity2 . @entity0 AND METHODS: Duodenal biopsies of seven subjects with positive anti-endomysial antibodies and normal histology underwent ultrastructural evaluation of the epithelial surface by means of both scanning and transmission electron microscopy. Specimens of intestinal mucosa of 14 @entity0 with non-celiac conditions were used as controls. RESULTS: In four @entity0 , electron microscopy revealed alterations of the enterocyte brush border with a significant reduction of the height of microvilli. After several months, three of them had a second biopsy that eventually showed histological modifications suggestive of @entity2 . In the other three @entity0 , no significant alteration of enterocyte ultrastructure was observed. One of them, rebiopsied after 12 months, still showed a normal duodenal histology. CONCLUSIONS: @entity2 can be associated with 'minimal' mucosal changes not detectable with conventional light microscopy. @entity1 , which primarily involve microvillous structure, may imply a reduction of intestinal absorptive surface already in the latent stage of the disease.

title: XXXX and 'normal' histology: is the intestinal mucosa really normal?

answer: @entity2


abstract: OBJECTIVE: To summarize the geographical and temporal variations in incidence of @entity3 in Europe, using the extensive data available from European general cancer registries, and consider these in light of recent trends in @entity2 extraction, use and import in European countries. MATERIAL AND METHODS: The data were extracted from the European @entity1 Incidence and Mortality database (EUROCIM). The inclusion criteria was acceptance in Volume VII of @entity1 Incidence in Five Continents. Truncated age-standardized rates per 100,000 for the ages 40-74 were used to summarise recent geographical variations. Standardized rate ratios and 95% confidence intervals for the periods 1986-1990 and 1991-1995 were compared to assess geographical variations in risk. To investigate changes in the magnitude of most recent trends, regression models fitted to the latest available 10-year period (1988-1997) were compared with trends in the previous decade. Fitted rates in younger (40-64) and older adults (65-74) in the most recent period were also compared. RESULTS: There was a great deal of geographical variation in the risk of @entity3 , annual rates ranging from around 8 per 100,000 in Scotland, England and The Netherlands, to lower than 1 per 100,000 in Spain (0.96), Estonia (0.85), Poland (0.85) and Yugoslavia, Vojvodina (0.56) among @entity0 . The rank of the rates for @entity0 was similar to that observed for @entity0 , although rates were considerably lower. Between 1978 and 1987, rates in @entity0 significantly increased in all countries (excepting Denmark). In the following 10 years, there was a deceleration in trend, and a significant increase was detectable only in England and France. In addition, the magnitude of recent trends in younger @entity0 was generally lower than those estimated for older @entity0 , in both national and regional cancer registry settings. CONCLUSIONS: While @entity3 incidence rates are still rising in Europe, a deceleration has started in some countries. A decrease may begin in the next few years in certain European populations considering the deceleration of observed trends in @entity3 and @entity2 exposure, as well as the recent ban on its use.

title: XXXX incidence in Europe: evidence of some deceleration in the increasing trends.

answer: @entity3


abstract: PURPOSE: To report the ocular manifestations of acute serologically confirmed @entity3 typhus. METHODS: A retrospective analysis of the clinical history, photography and fluorescein angiography of two @entity0 with acute @entity3 typhus with ocular involvement was conducted. RESULTS: A 38 year old male and a 49 year old female were included in the study. Both complained of @entity5 , @entity2 , @entity8 , night sweats and @entity6 . They had noted the recent onset of diminished visual acuity and floaters. Examination of the posterior pole revealed mild optic nerve head @entity1 (in one @entity0 ), @entity7 and small localized areas of retinal whitening. The history confirmed that both @entity0 had been exposed to fleas and the serologic testing was positive for @entity10 . The systemic and ocular findings resolved after the use of systemic antibiotics. CONCLUSION: @entity4 such as @entity3 typhus should be included in the differential diagnosis of otherwise healthy individuals who present with an acute systemic @entity5 and @entity9 or @entity9 . SUMMARY STATEMENT: The clinical features of two @entity0 with serologically proven acute @entity3 typhus with ocular involvement are presented. Both @entity0 presented with a retinal whitening that resolved after treatment.

title: Retinal manifestations of acute XXXX typhus.

answer: @entity3


abstract: The use of natural antioxidants and @entity7 in nutritional and pharmaceutical applications is increasing. Because some phytochemicals such as @entity3 , found in soy products, have estrogenic activity, we investigated the estrogenic potential of a natural antioxidant mixture ( @entity4 ) isolated from @entity6 leaves, using an in vivo uterotrophic bioassay and an in vitro transcriptional activation assay for the @entity2 receptor (ER). Outbred female @entity5 @entity0 (17 d old) were given subcutaneous injections of @entity1 or @entity3 [500 and 500,000 microg /(kg x d), respectively] as positive controls or @entity4 [1000 to 1,000,000 microg/(kg x d)] for 3 d. Uterine wet weight/body weight ratios were determined. Both @entity1 and @entity3 significantly increased uterine wet weight ratios compared with untreated controls, but @entity4 did not. Histological examination of the uterus showed that @entity1 and @entity3 increased epithelial cell height, number and gland development, but @entity4 did not. Estrogenic activity of @entity4 was investigated in vitro using the ER transcriptional activation assay. BG1Luc4E2 cells expressing ER were stably transfected with a luciferase reporter gene responsive to @entity2 . @entity1 dose dependently increased luciferase activity; @entity4 had no effect. When @entity4 was tested for antiestrogenic activity, it did not lessen the effects of @entity1 . These data suggest that @entity4 does not have estrogenic or antiestrogenic activity. Thus, an antioxidant mixture has been identified that does not have potentially adverse estrogenic activity.

title: A natural antioxidant mixture from XXXX does not have estrogenic or antiestrogenic activity in immature @entity5 @entity0 .

answer: @entity6


abstract: The use of natural antioxidants and @entity7 in nutritional and pharmaceutical applications is increasing. Because some phytochemicals such as @entity3 , found in soy products, have estrogenic activity, we investigated the estrogenic potential of a natural antioxidant mixture ( @entity4 ) isolated from @entity6 leaves, using an in vivo uterotrophic bioassay and an in vitro transcriptional activation assay for the @entity2 receptor (ER). Outbred female @entity5 @entity0 (17 d old) were given subcutaneous injections of @entity1 or @entity3 [500 and 500,000 microg /(kg x d), respectively] as positive controls or @entity4 [1000 to 1,000,000 microg/(kg x d)] for 3 d. Uterine wet weight/body weight ratios were determined. Both @entity1 and @entity3 significantly increased uterine wet weight ratios compared with untreated controls, but @entity4 did not. Histological examination of the uterus showed that @entity1 and @entity3 increased epithelial cell height, number and gland development, but @entity4 did not. Estrogenic activity of @entity4 was investigated in vitro using the ER transcriptional activation assay. BG1Luc4E2 cells expressing ER were stably transfected with a luciferase reporter gene responsive to @entity2 . @entity1 dose dependently increased luciferase activity; @entity4 had no effect. When @entity4 was tested for antiestrogenic activity, it did not lessen the effects of @entity1 . These data suggest that @entity4 does not have estrogenic or antiestrogenic activity. Thus, an antioxidant mixture has been identified that does not have potentially adverse estrogenic activity.

title: A natural antioxidant mixture from @entity6 does not have estrogenic or antiestrogenic activity in immature XXXX @entity0 .

answer: @entity5


abstract: The use of natural antioxidants and @entity7 in nutritional and pharmaceutical applications is increasing. Because some phytochemicals such as @entity3 , found in soy products, have estrogenic activity, we investigated the estrogenic potential of a natural antioxidant mixture ( @entity4 ) isolated from @entity6 leaves, using an in vivo uterotrophic bioassay and an in vitro transcriptional activation assay for the @entity2 receptor (ER). Outbred female @entity5 @entity0 (17 d old) were given subcutaneous injections of @entity1 or @entity3 [500 and 500,000 microg /(kg x d), respectively] as positive controls or @entity4 [1000 to 1,000,000 microg/(kg x d)] for 3 d. Uterine wet weight/body weight ratios were determined. Both @entity1 and @entity3 significantly increased uterine wet weight ratios compared with untreated controls, but @entity4 did not. Histological examination of the uterus showed that @entity1 and @entity3 increased epithelial cell height, number and gland development, but @entity4 did not. Estrogenic activity of @entity4 was investigated in vitro using the ER transcriptional activation assay. BG1Luc4E2 cells expressing ER were stably transfected with a luciferase reporter gene responsive to @entity2 . @entity1 dose dependently increased luciferase activity; @entity4 had no effect. When @entity4 was tested for antiestrogenic activity, it did not lessen the effects of @entity1 . These data suggest that @entity4 does not have estrogenic or antiestrogenic activity. Thus, an antioxidant mixture has been identified that does not have potentially adverse estrogenic activity.

title: A natural antioxidant mixture from @entity6 does not have estrogenic or antiestrogenic activity in immature @entity5 XXXX .

answer: @entity0


abstract: In individuals with @entity4 , childhood manifestations are usually predictive of a more severe phenotype. Although @entity0 with @entity4 are at risk of irreversible disease complications, early intervention with an optimal dose of enzyme therapy can prevent the development of complications and ensure adequate, potentially normal, development through childhood and adolescence. Very few, if any, @entity0 diagnosed by signs and symptoms should go untreated. Evidence suggests that disease severity, disease progression and treatment response in different organs where glucocerebroside accumulates are often non-uniform in affected individuals. Therefore, serial monitoring of the affected compartments is important. This should include a thorough physical examination at 6- to 12-monthly intervals. Neurological assessment should be performed to rule out neurological involvement and should be undertaken periodically thereafter in @entity0 who are considered to have risk factors for developing @entity1 . Haematological and biochemical markers, such as haemoglobin, platelet counts and chitotriosidase levels, should be assessed every 3 months initially, but when clinical goals have been met through treatment with enzyme therapy, the frequency can be reduced to every 12 to 24 months. Careful monitoring of @entity2 is vitally important, as the resulting sequelae are associated with the greatest level of morbidity. By combining various imaging modalities, the skeletal complications of @entity4 can be effectively monitored so that irreversible skeletal pathology is avoided and @entity3 due to bone involvement is diminished or eliminated. Monitoring must include regular psychosocial, functional status and quality-of-life evaluation, as well as consistent assessment of therapeutic goal attainment and necessary dosage adjustments based on the @entity0 's progress. CONCLUSION: Through comprehensive and serial monitoring, ultimately, a therapeutic dose of enzyme therapy that achieves sustained benefits can be found for each @entity0 with non-neuronpathic @entity4 .

title: Paediatric XXXX : recommendations for treatment and monitoring.

answer: @entity4


abstract: BACKGROUND: As a complication of chemotherapy/corticosteroids for the treatment of @entity3 ( @entity3 ) and other @entity1 during childhood, avascular @entity4 appears in up to 30 % of the @entity0 . Weight-bearing joints are involved in over 90 % of the cases. Total joint replacement is often necessary to restore function. Yet, endoprostheses in young @entity0 again bare the risk of later complications and the need for several revision surgeries. In this report, joint preserving surgical strategies will be discussed. @entity0 : Three hips and eleven knee joints in 8 @entity0 (4 male, 4 female) were operated on for symptomatic ON and/or @entity5 ( @entity5 ) after chemotherapy. Four of the @entity0 underwent surgery in more than one joint. The average age at the time of surgery was 18 years (range 14 - 26). The procedures included retrograde drilling (core decompression), bone grafting, implantation of collagen sponges with autologous bone marrow aspirate, osteochondral autograft transplantation and transplantation of periosteal flaps. Two hip joints underwent total joint replacement. Average follow up was 25 months. RESULTS: After an average follow up of 2 years, all @entity0 were satisfied with the functional results after the last follow up with @entity2 free walking for a minimum of 60 minutes. No night @entity2 was reported. One @entity0 complained about intermittent periods of dysaesthesia around the bone harvest area at the iliac crest. CONCLUSIONS: The aim of surgery for ON and @entity5 after chemotherapy should be the reduction of @entity2 and preservation of the joint to bypass the risks of joint replacement in young @entity0 , although total joint replacement may become indicated in endstage degeneration of the involved joint.

title: Joint preserving surgery for @entity4 and XXXX after chemotherapy in childhood.

answer: @entity5


abstract: BACKGROUND: As a complication of chemotherapy/corticosteroids for the treatment of @entity3 ( @entity3 ) and other @entity1 during childhood, avascular @entity4 appears in up to 30 % of the @entity0 . Weight-bearing joints are involved in over 90 % of the cases. Total joint replacement is often necessary to restore function. Yet, endoprostheses in young @entity0 again bare the risk of later complications and the need for several revision surgeries. In this report, joint preserving surgical strategies will be discussed. @entity0 : Three hips and eleven knee joints in 8 @entity0 (4 male, 4 female) were operated on for symptomatic ON and/or @entity5 ( @entity5 ) after chemotherapy. Four of the @entity0 underwent surgery in more than one joint. The average age at the time of surgery was 18 years (range 14 - 26). The procedures included retrograde drilling (core decompression), bone grafting, implantation of collagen sponges with autologous bone marrow aspirate, osteochondral autograft transplantation and transplantation of periosteal flaps. Two hip joints underwent total joint replacement. Average follow up was 25 months. RESULTS: After an average follow up of 2 years, all @entity0 were satisfied with the functional results after the last follow up with @entity2 free walking for a minimum of 60 minutes. No night @entity2 was reported. One @entity0 complained about intermittent periods of dysaesthesia around the bone harvest area at the iliac crest. CONCLUSIONS: The aim of surgery for ON and @entity5 after chemotherapy should be the reduction of @entity2 and preservation of the joint to bypass the risks of joint replacement in young @entity0 , although total joint replacement may become indicated in endstage degeneration of the involved joint.

title: Joint preserving surgery for XXXX and @entity5 after chemotherapy in childhood.

answer: @entity4


abstract: A significant proportion of @entity0 with @entity1 are @entity4 . It is not clear if this affects response to treatment because few studies have systematically examined treatment effects on sleep in @entity0 with @entity1 . Reported herein are the results of what we believe to be the first study of the effects of the @entity2 oxidase inhibitor @entity5 (average dose=37 mg/day) on the sleep of @entity0 with @entity1 .Twenty-three @entity0 with anergic @entity1 completed sleep studies before and after pharmacotherapy. Changes in polysomnographic variables were examined using paired t tests. The @entity0 experienced a 40% reduction in @entity3 ( @entity3 ) sleep time, as well as significant decreases in @entity3 percentage, @entity3 activity, number of @entity3 periods, and @entity3 intensity. @entity3 latency was prolonged by nearly 3-fold. The decrease in @entity3 sleep was accompanied by a modest (8%) reduction in total sleep time and increased "light" sleep. There was no change in sleep continuity indices or slow wave sleep. Correlational analyses suggested that antidepressant response was only weakly associated with changes in @entity3 sleep. These findings indicate that @entity5 's effects on @entity3 sleep greatly surpass effects on sleep architecture or sleep maintenance. Moreover, effective treatment of @entity1 did not "normalize" the @entity4 associated with @entity1 .

title: Effects of @entity5 on the sleep of @entity0 with anergic XXXX .

answer: @entity1


abstract: A significant proportion of @entity0 with @entity1 are @entity4 . It is not clear if this affects response to treatment because few studies have systematically examined treatment effects on sleep in @entity0 with @entity1 . Reported herein are the results of what we believe to be the first study of the effects of the @entity2 oxidase inhibitor @entity5 (average dose=37 mg/day) on the sleep of @entity0 with @entity1 .Twenty-three @entity0 with anergic @entity1 completed sleep studies before and after pharmacotherapy. Changes in polysomnographic variables were examined using paired t tests. The @entity0 experienced a 40% reduction in @entity3 ( @entity3 ) sleep time, as well as significant decreases in @entity3 percentage, @entity3 activity, number of @entity3 periods, and @entity3 intensity. @entity3 latency was prolonged by nearly 3-fold. The decrease in @entity3 sleep was accompanied by a modest (8%) reduction in total sleep time and increased "light" sleep. There was no change in sleep continuity indices or slow wave sleep. Correlational analyses suggested that antidepressant response was only weakly associated with changes in @entity3 sleep. These findings indicate that @entity5 's effects on @entity3 sleep greatly surpass effects on sleep architecture or sleep maintenance. Moreover, effective treatment of @entity1 did not "normalize" the @entity4 associated with @entity1 .

title: Effects of XXXX on the sleep of @entity0 with anergic @entity1 .

answer: @entity5


abstract: A significant proportion of @entity0 with @entity1 are @entity4 . It is not clear if this affects response to treatment because few studies have systematically examined treatment effects on sleep in @entity0 with @entity1 . Reported herein are the results of what we believe to be the first study of the effects of the @entity2 oxidase inhibitor @entity5 (average dose=37 mg/day) on the sleep of @entity0 with @entity1 .Twenty-three @entity0 with anergic @entity1 completed sleep studies before and after pharmacotherapy. Changes in polysomnographic variables were examined using paired t tests. The @entity0 experienced a 40% reduction in @entity3 ( @entity3 ) sleep time, as well as significant decreases in @entity3 percentage, @entity3 activity, number of @entity3 periods, and @entity3 intensity. @entity3 latency was prolonged by nearly 3-fold. The decrease in @entity3 sleep was accompanied by a modest (8%) reduction in total sleep time and increased "light" sleep. There was no change in sleep continuity indices or slow wave sleep. Correlational analyses suggested that antidepressant response was only weakly associated with changes in @entity3 sleep. These findings indicate that @entity5 's effects on @entity3 sleep greatly surpass effects on sleep architecture or sleep maintenance. Moreover, effective treatment of @entity1 did not "normalize" the @entity4 associated with @entity1 .

title: Effects of @entity5 on the sleep of XXXX with anergic @entity1 .

answer: @entity0


abstract: PURPOSE: Our aim was to determine the outcome of arthroscopic-assisted reduction with bilateral buttress plate fixation for the treatment of @entity8 . TYPE OF STUDY: Case series. METHODS: 18 consecutive @entity0 (12 @entity0 , 6 @entity0 ) with @entity2 were enrolled in this prospective study. All @entity0 underwent arthroscopic-assisted bilateral buttress plate fixation of @entity8 . The average age at operation was 35 years (range, 23 to 45 years). The follow-up period ranged from 39 to 69 months, with an average of 48 months. Using the Schatzker classification, there were 11 type V and 7 type VI @entity2 . The clinical and radiological outcomes were determined according to Rasmussen's system. RESULTS: All of the 18 @entity2 united. Overall, 4 (22%) @entity0 were rated as excellent, 12 (67%) good, and 2 (11%) fair. Secondary @entity6 appeared in 3 injured knees (16.7%). One @entity0 had a wound dehiscence (3 cm long) of the medial incision. @entity5 was noted in 3 @entity0 without functional instability. Two @entity0 had valgus alignment between 10 degrees and 15 degrees. Two @entity0 had the paresthesia over the lateral @entity4 . There were no complications directly associated with arthroscopy in any of the 18 @entity0 . No @entity7 , @entity3 , or knee stiffness was found at final follow-up. CONCLUSIONS: Arthroscopic-assisted reduction with bilateral buttress plate fixation for @entity2 allows accurate @entity2 reduction, diagnosis, and treatment of associated @entity1 , and less dissection than open reduction internal fixation.

title: Arthroscopic-assisted reduction with bilateral buttress plate XXXX .

answer: @entity2


abstract: The incidence of @entity0 increases with advancing age. In view of the progressive aging of the population, this problem will tend to become more and more frequent. At present, @entity1 of advanced age are often "undertreated" owing to the mistaken prejudice that older @entity1 are unable to withstand standard multimodal therapy for this disease. In fact, there is no scientific evidence to that effect. Treatment choices should therefore be largely comparable to those adopted in younger @entity1 . Even chemotherapy, which encounters the strongest resistance, by @entity1 but also by doctors, should be administered when indicated. A number of studies have demonstrated that the toxic and side effects observed in elderly @entity1 are comparable to those observed in younger age groups. In practice, particular attention needs to be paid when administering cytostatic treatment to @entity1 over 80 years of age. Very conservative treatment ( @entity2 plus radiotherapy) may be reserved only to particularly frail elderly @entity1 . In conclusion, the therapeutic choice should depend more on assessment of the biological age, life expectancy and @entity1 's expectations than on the anagraphic age.

title: [ XXXX in advanced age].

answer: @entity0


abstract: The aim of the present study was to investigate local vascular and sensory changes and their correlation in order to obtain a better understanding of the mechanisms of @entity2 , @entity2 and vascular changes following tissue @entity0 induced by repetitive application of @entity3 cream. This type of application was utilized as a controlled model of @entity0 which was altered in intensity due to its repetitive applicability. Ten healthy volunteers participated in two experiments separated by at least five days. Each experiment consisted of a baseline session followed by five additional sessions. Before these sessions either 1.5 g @entity3 (1%) or placebo cream was applied to the volar site of the forearm for 15 min. The areas of stroking @entity2 and pin-prick @entity2 were mapped and the intensity of spontaneous @entity1 (VAS) was assessed after each application of the cream. In addition, the visible flare, temperature (IR-Thermography), and blood- flow (Laser-Doppler) were measured. The first application of @entity3 was perceived as painful; it induced both @entity2 and @entity2 . Compared to placebo, the first application of @entity3 cream also resulted in an increased blood-flow, elevated temperature and visible flare. The highest values of these sensory and vascular parameters were reached after the third application. A direct correlation between visible flare, secondary @entity2 and @entity2 following repetitive application of @entity3 indicates that both common central and peripheral mechanisms were involved in these changes.

title: Correlation between local vascular and sensory changes following tissue @entity0 induced by repetitive application of topical XXXX .

answer: @entity3


abstract: The aim of the present study was to investigate local vascular and sensory changes and their correlation in order to obtain a better understanding of the mechanisms of @entity2 , @entity2 and vascular changes following tissue @entity0 induced by repetitive application of @entity3 cream. This type of application was utilized as a controlled model of @entity0 which was altered in intensity due to its repetitive applicability. Ten healthy volunteers participated in two experiments separated by at least five days. Each experiment consisted of a baseline session followed by five additional sessions. Before these sessions either 1.5 g @entity3 (1%) or placebo cream was applied to the volar site of the forearm for 15 min. The areas of stroking @entity2 and pin-prick @entity2 were mapped and the intensity of spontaneous @entity1 (VAS) was assessed after each application of the cream. In addition, the visible flare, temperature (IR-Thermography), and blood- flow (Laser-Doppler) were measured. The first application of @entity3 was perceived as painful; it induced both @entity2 and @entity2 . Compared to placebo, the first application of @entity3 cream also resulted in an increased blood-flow, elevated temperature and visible flare. The highest values of these sensory and vascular parameters were reached after the third application. A direct correlation between visible flare, secondary @entity2 and @entity2 following repetitive application of @entity3 indicates that both common central and peripheral mechanisms were involved in these changes.

title: Correlation between local vascular and sensory changes following tissue XXXX induced by repetitive application of topical @entity3 .

answer: @entity0


abstract: BACKGROUND: Endotoxin is a major stimulus for triggering the host response in @entity3 . The pathophysiology of @entity3 involves activation of the vascular endothelium and leukocytes, resulting in the release of various mediators, e.g. cytokines, @entity5 (NO), endothelin (ET-1) and complement factors. We evaluated the blood levels of complement activation, ET-1 and @entity9 (NPY) in parallel with the haemodynamic and @entity1 transport response during @entity0 experimental @entity8 . METHODS: Eleven healthy @entity0 had venous, arterial and pulmonary arterial catheters placed for continuous haemodynamic measuring. After 30 min rest endotoxin ( @entity4 4 ng kg(-1), Lot G1) was intravenously administered. Blood samples from pulmonary and arterial catheters were collected hourly over 4 h. RESULTS: Body temperature augmented significantly from baseline values (36.7 +/- 0.7 degrees C, mean +/- SEM) with a maximum after 3.5 h (39.1 +/- 0.3 degrees C, P < 0.001). Cardiac output increased by 100%, systemic vascular resistance decreased by 50%, the @entity1 consumption and the tissue @entity1 transport increased. Activation of the complement system was indicated by an increase in SC5b-9. @entity6 -like immunoreactivity (ET-1- @entity7 ) increased over time in arterial blood. NPY-like immunoreactivity (NPY- @entity7 ) did not change over time. CONCLUSION: A dose of endotoxin associated with reproducible systemic vasodilation and fever in healthy subjects causes complement activation and increased systemic levels of ET-1- @entity7 , illustrating that the model is a useful tool for inducing moderate systemic @entity2 where several mediator systems are activated.

title: Complement activation, XXXX and @entity9 in relation to the cardiovascular response to endotoxin-induced systemic @entity2 in healthy volunteers.

answer: @entity6


abstract: BACKGROUND: Endotoxin is a major stimulus for triggering the host response in @entity3 . The pathophysiology of @entity3 involves activation of the vascular endothelium and leukocytes, resulting in the release of various mediators, e.g. cytokines, @entity5 (NO), endothelin (ET-1) and complement factors. We evaluated the blood levels of complement activation, ET-1 and @entity9 (NPY) in parallel with the haemodynamic and @entity1 transport response during @entity0 experimental @entity8 . METHODS: Eleven healthy @entity0 had venous, arterial and pulmonary arterial catheters placed for continuous haemodynamic measuring. After 30 min rest endotoxin ( @entity4 4 ng kg(-1), Lot G1) was intravenously administered. Blood samples from pulmonary and arterial catheters were collected hourly over 4 h. RESULTS: Body temperature augmented significantly from baseline values (36.7 +/- 0.7 degrees C, mean +/- SEM) with a maximum after 3.5 h (39.1 +/- 0.3 degrees C, P < 0.001). Cardiac output increased by 100%, systemic vascular resistance decreased by 50%, the @entity1 consumption and the tissue @entity1 transport increased. Activation of the complement system was indicated by an increase in SC5b-9. @entity6 -like immunoreactivity (ET-1- @entity7 ) increased over time in arterial blood. NPY-like immunoreactivity (NPY- @entity7 ) did not change over time. CONCLUSION: A dose of endotoxin associated with reproducible systemic vasodilation and fever in healthy subjects causes complement activation and increased systemic levels of ET-1- @entity7 , illustrating that the model is a useful tool for inducing moderate systemic @entity2 where several mediator systems are activated.

title: Complement activation, @entity6 and XXXX in relation to the cardiovascular response to endotoxin-induced systemic @entity2 in healthy volunteers.

answer: @entity9


abstract: BACKGROUND: Endotoxin is a major stimulus for triggering the host response in @entity3 . The pathophysiology of @entity3 involves activation of the vascular endothelium and leukocytes, resulting in the release of various mediators, e.g. cytokines, @entity5 (NO), endothelin (ET-1) and complement factors. We evaluated the blood levels of complement activation, ET-1 and @entity9 (NPY) in parallel with the haemodynamic and @entity1 transport response during @entity0 experimental @entity8 . METHODS: Eleven healthy @entity0 had venous, arterial and pulmonary arterial catheters placed for continuous haemodynamic measuring. After 30 min rest endotoxin ( @entity4 4 ng kg(-1), Lot G1) was intravenously administered. Blood samples from pulmonary and arterial catheters were collected hourly over 4 h. RESULTS: Body temperature augmented significantly from baseline values (36.7 +/- 0.7 degrees C, mean +/- SEM) with a maximum after 3.5 h (39.1 +/- 0.3 degrees C, P < 0.001). Cardiac output increased by 100%, systemic vascular resistance decreased by 50%, the @entity1 consumption and the tissue @entity1 transport increased. Activation of the complement system was indicated by an increase in SC5b-9. @entity6 -like immunoreactivity (ET-1- @entity7 ) increased over time in arterial blood. NPY-like immunoreactivity (NPY- @entity7 ) did not change over time. CONCLUSION: A dose of endotoxin associated with reproducible systemic vasodilation and fever in healthy subjects causes complement activation and increased systemic levels of ET-1- @entity7 , illustrating that the model is a useful tool for inducing moderate systemic @entity2 where several mediator systems are activated.

title: Complement activation, @entity6 and @entity9 in relation to the cardiovascular response to endotoxin-induced systemic XXXX in healthy volunteers.

answer: @entity2


abstract: VDD pacing provides the physiological benefits of atrioventricular synchronous pacing with the convenience of a single lead system, but is hampered by uncertainty regarding long-term atrial sensing and potential development of @entity2 . To examine the long-term reliability and complication rates of VDD pacing, we compared the outcome of 112 consecutive @entity0 (age 70 +/- 13 years, 59% male) with symptomatic @entity1 who received a single pass bipolar VDD system to 80 @entity0 (age 63 +/- 16 years, 70% male) who received @entity3 pacing for the same indication. All @entity0 were judged to have intact sinus node function based on submitted ECGs and monitoring results at the time of implant. Implant time was reduced in VDD @entity0 compared to @entity3 @entity0 (63 +/- 20 vs 97 +/- 36 minutes, P < 0.0001). Implant complications occurred in 5 (6%) @entity3 @entity0 compared to 3 (3%) VDD @entity0 (P = 0.15). The implant P wave was lower with VDD pacing compared to @entity3 @entity0 (2.91 +/- 1.48 vs 4.0 +/- 1.7 mV, P < 0.0001), but remained stable during long-term follow-up in both groups. During 17.7 +/- 10.0 months of follow-up in the VDD group, only 2 VDD @entity0 were reprogrammed to VVIR mode, compared to 3 @entity3 @entity0 . Physiological atrioventricular activation was maintained in 94%-99% of beats throughout the follow-up period in the VDD group. VDD pacing is an excellent strategy for treatment of @entity0 with symptomatic @entity1 . The lower cost, high reliability, and abbreviated implantation time suggest that VDD pacing is a viable alternative to @entity3 pacing in @entity0 with high-degree @entity1 and normal sinus node function.

title: Optimal pacing for symptomatic @entity1 : a comparison of VDD and XXXX pacing.

answer: @entity3


abstract: VDD pacing provides the physiological benefits of atrioventricular synchronous pacing with the convenience of a single lead system, but is hampered by uncertainty regarding long-term atrial sensing and potential development of @entity2 . To examine the long-term reliability and complication rates of VDD pacing, we compared the outcome of 112 consecutive @entity0 (age 70 +/- 13 years, 59% male) with symptomatic @entity1 who received a single pass bipolar VDD system to 80 @entity0 (age 63 +/- 16 years, 70% male) who received @entity3 pacing for the same indication. All @entity0 were judged to have intact sinus node function based on submitted ECGs and monitoring results at the time of implant. Implant time was reduced in VDD @entity0 compared to @entity3 @entity0 (63 +/- 20 vs 97 +/- 36 minutes, P < 0.0001). Implant complications occurred in 5 (6%) @entity3 @entity0 compared to 3 (3%) VDD @entity0 (P = 0.15). The implant P wave was lower with VDD pacing compared to @entity3 @entity0 (2.91 +/- 1.48 vs 4.0 +/- 1.7 mV, P < 0.0001), but remained stable during long-term follow-up in both groups. During 17.7 +/- 10.0 months of follow-up in the VDD group, only 2 VDD @entity0 were reprogrammed to VVIR mode, compared to 3 @entity3 @entity0 . Physiological atrioventricular activation was maintained in 94%-99% of beats throughout the follow-up period in the VDD group. VDD pacing is an excellent strategy for treatment of @entity0 with symptomatic @entity1 . The lower cost, high reliability, and abbreviated implantation time suggest that VDD pacing is a viable alternative to @entity3 pacing in @entity0 with high-degree @entity1 and normal sinus node function.

title: Optimal pacing for symptomatic XXXX : a comparison of VDD and @entity3 pacing.

answer: @entity1


abstract: We examined whether the detection of dysgranulopoiesis in blood or bone marrow would predict @entity2 ( @entity2 ) in transformation in 31 cases that fulfilled World Health Organization criteria for disease transformation, including 14 in accelerated phase (AP), 10 in @entity3 ( @entity3 ), and 7 in @entity0 ( @entity0 ). Dysgranulopoiesis was detected in 7 cases, 6 in AP and 1 in @entity3 , but not in @entity0 or chronic phase cases. In 3 AP cases, dysgranulopoiesis was identified 2 to 5 months before the morphologic diagnosis of transformation. Two AP cases showed no dysgranulopoiesis in previous blood or marrow smears. For 2 cases (1 AP and 1 @entity3 ), no previous blood or marrow specimens were available. Cytogenetic information was available for 6 of 7 cases with and 22 of 24 cases without dysgranulopoiesis. All cases with dysgranulopoiesis had secondary chromosome abnormalities in addition to t(9;22). In 5 (83%) of 6 cases with dysgranulopoiesis, the secondary chromosome abnormalities included @entity1 . In contrast, none of the 22 cases of @entity2 in AP or BC but without dysgranulopoiesis showed 17p abnormalities (P = .001). Our findings demonstrated that dysgranulopoiesis was associated strongly with chromosome 17p abnormalities and may indicate the onset of or impending disease transformation.

title: Diagnostic significance of detecting dysgranulopoiesis in XXXX .

answer: @entity2


abstract: PURPOSE: This study aimed to evaluate the prognostic significance of the modified Glasgow Prognostic Score (mGPS) in @entity0 with @entity4 ( @entity4 ) who received stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Data from 165 @entity0 who underwent SBRT for stage I @entity4 with histologic confirmation from January 1999 to September 2010 were collected retrospectively. Factors, including age, performance status, histology, Charlson comorbidity index, mGPS, and recursive partitioning analysis (RPA) class based on sex and T stage, were evaluated with regard to @entity5 ( @entity5 ) using the Cox proportional hazards model. The impact of the mGPS on cause of @entity3 and failure patterns was also analyzed. RESULTS: The 3-year @entity5 was 57.9%, with a median follow-up time of 3.5 years. A higher mGPS correlated significantly with poor @entity5 (P<.001). The 3-year @entity5 of lower mGPS @entity0 was 66.4%, whereas that of higher mGPS @entity0 was 44.5%. On multivariate analysis, mGPS and RPA class were significant factors for @entity5 . A higher mGPS correlated significantly with @entity1 @entity3 (P=.019) and distant @entity2 (P=.013). CONCLUSIONS: The mGPS was a significant predictor of clinical outcomes for SBRT in @entity4 @entity0 .

title: Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage XXXX .

answer: @entity4


abstract: Recognition of Ras by its downstream target @entity0 is mediated by a Ras-recognition region in the Ras-binding domain (RBD) of @entity0 . Residues 78-89 in this region occupy two different conformations in the ensemble of NMR solution structures of the RBD: a fully alpha-helical one, and one where 87-90 form a type IV beta-turn. Molecular dynamics simulations of the RBD in solution were performed to explore the stability of these and other possible conformations of both the wild-type RBD and the @entity1 mutant, which does not bind Ras. The simulations sample a fully helical conformation for residues 78-89 similar to the NMR helical structures, a conformation where 85-89 form a 3(10)-helical turn, and a conformation where 87-90 form a type I beta-turn, whose free energies are all within 0.3 kcal/mol of each other. NOE patterns and H(alpha) chemical shifts from the simulations are in reasonable agreement with experiment. The NMR turn structure is calculated to be 3 kcal/mol higher than the three above conformations. In a simulation with the same implicit solvent model used in the NMR structure generation, the turn conformation relaxes into the fully helical conformation, illustrating possible structural artifacts introduced by the implicit solvent model. With the @entity0 @entity1 mutant, simulations sample a fully helical and a turn conformation, the turn being 0.9 kcal/mol more stable. Thus, the mutation affects the population of RBD conformations, and this is expected to affect Ras binding. For example, if the fully helical conformation of residues 78-89 is required for binding, its free energy increase in @entity1 will increase the binding free energy by about 0.6 kcal/mol.

title: Conformation of the Ras-binding domain of XXXX studied by molecular dynamics and free energy simulations.

answer: @entity0


abstract: BACKGROUND: Because of the deinstitutionalization of mental health care in Hong Kong that has taken place since the 1980s, many @entity0 with mental health problems are being cared for in the community. The majority of clients have a diagnosis of @entity2 , and many have a long duration of illness and multiple readmissions. There is concern about their quality of life. AIM: To investigate quality of life and related factors in clients with a diagnosis of @entity2 in Hong Kong. DESIGN: A convenience sample was recruited from a @entity1 outpatient department. Structured face-to-face interviews were conducted using the Brief Psychiatric Rating Scale and the Hong Kong Chinese World Health Organization Quality of Life Scale-Brief Version. RESULTS: A total of 172 @entity0 participated in the study. Most of them were single and unemployed. They were least satisfied with their psychological health, financial situation, life enjoyment and sexual activity. @entity0 (n = 91) reported less satisfaction with quality of life than @entity0 (n = 86). Unemployed @entity0 (n = 100) were less satisfied with their quality of life than the employed (n = 76). Higher levels of mental health problems and higher numbers of previous hospitalizations were associated with negative perceptions of quality of life. DISCUSSION: @entity0 with mental health problems had significantly less satisfaction with their quality of life than a sample from the general population in Hong Kong surveyed in a previous study. As well as experiencing distressing mental symptoms, they had many difficulties, such as financial problems, unemployment and lack of opportunities to participate in social activities, that resulted from stigma and discrimination. These had a great impact on their quality of life. STUDY LIMITATIONS: Because of the small sample size and its convenience nature, the findings may not be generalizable to all clients in Hong Kong. A generic instrument was used to measure quality of life, and this may not have been sensitive to certain aspects of mental health clients' lives. CONCLUSION: The findings suggest that there is a need to strengthen social and vocational rehabilitation for @entity0 with mental health problems in Hong Kong. A more holistic and intensive model of care is required to meet their complex needs. A larger and more diverse sample should be used in future research, and a quality of life measure specifically designed for @entity0 with mental health problems should be used.

title: Quality of life of clients with XXXX .

answer: @entity2


abstract: PURPOSE: @entity10 in renal transplant recipients have historically been associated with mortality rates as high as 50 to 100 percent. However, these previous series generally predate the use of @entity3 -based immunosuppressive protocols. METHODS: We retrospectively reviewed all @entity0 who had undergone renal transplant from our institution and who developed complicated @entity11 . @entity9 was defined as @entity11 involving free perforation, abscess, phlegmon, or @entity5 . Factors analyzed included the time interval since transplantation, use of @entity3 , living-related vs. cadaveric donor, cause of @entity2 , and presenting signs and symptoms. RESULTS: Between August 1969 and September 1996, 1,211 kidney transplants were performed in 1,137 @entity0 . The first 388 @entity0 (1969-1984) received @entity4 and @entity7 , with @entity3 added to the immunosuppressive regimen for the subsequent 823 recipients (1984-1996). Thirteen (1.1 percent) @entity0 had episodes of complicated @entity11 , occurring from 25 days to 14 years after transplant; all required surgical therapy. Clinical presentation was highly variable, ranging from asymptomatic @entity8 (2 @entity0 ) to generalized @entity6 . There was one perioperative mortality (7.7 percent). @entity0 with @entity1 as the cause of @entity2 had a significantly higher rate of complicated @entity11 . Specifically, @entity0 with @entity1 (9 percent of the total transplant population) accounted for 46 percent of the cases of @entity11 (P < 0.001, Fisher's exact probability test). Neither treatment with @entity3 nor donor source had a significant effect on the rate of diverticular complications (P = 0.36 and P = 0.99, respectively, Fisher's exact probability test). CONCLUSION: @entity9 following renal transplantation is rare, and the clinical presentation may be atypical in the immunosuppressed transplant recipient. @entity0 with @entity1 experience a significantly higher rate of complicated @entity11 than do other transplant @entity0 and, therefore, warrant aggressive diagnostic evaluation of even vague abdominal symptoms. In addition, pretransplant screening and prophylactic sigmoid resection in this high-risk population deserve consideration and further study.

title: XXXX following renal transplantation.

answer: @entity9


abstract: The objective of this study was to evaluate the potential survival benefit of debulking macroscopic @entity3 and other clinical prognostic factors among @entity0 with node-positive @entity2 . Demographic, operative, pathologic, and follow-up data were abstracted retrospectively for 41 eligible @entity0 with FIGO stage IIIC @entity2 . Survival curves were generated using the Kaplan-Meier method and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. All @entity0 had positive pelvic lymph nodes and 20 @entity0 (48.8%) had positive para-aortic lymph nodes. Postoperatively, all @entity0 received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 @entity0 received chemotherapy. The median @entity1 ( @entity1 ) time for all @entity0 was 30.6 months (median follow-up 34. 0 months). @entity0 with completely resected macroscopic lymphadenopathy had a significantly longer median @entity1 time (37.5 months), compared to @entity0 left with gross residual @entity1 (8.8 months, P = 0.006). On multivariate analysis, independent predictors of @entity1 were gross residual @entity1 (HR 7.96, 95% CI 2.54-24.97, P < 0. 001), age > or = 65 years (HR 6.22, 95% CI 2.05-18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95% CI 0.07-0.76, P = 0.016). We conclude that in @entity0 with @entity2 , complete resection of macroscopic @entity1 and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.

title: FIGO @entity2 : resection of macroscopic XXXX and other determinants of survival.

answer: @entity1


abstract: The objective of this study was to evaluate the potential survival benefit of debulking macroscopic @entity3 and other clinical prognostic factors among @entity0 with node-positive @entity2 . Demographic, operative, pathologic, and follow-up data were abstracted retrospectively for 41 eligible @entity0 with FIGO stage IIIC @entity2 . Survival curves were generated using the Kaplan-Meier method and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. All @entity0 had positive pelvic lymph nodes and 20 @entity0 (48.8%) had positive para-aortic lymph nodes. Postoperatively, all @entity0 received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 @entity0 received chemotherapy. The median @entity1 ( @entity1 ) time for all @entity0 was 30.6 months (median follow-up 34. 0 months). @entity0 with completely resected macroscopic lymphadenopathy had a significantly longer median @entity1 time (37.5 months), compared to @entity0 left with gross residual @entity1 (8.8 months, P = 0.006). On multivariate analysis, independent predictors of @entity1 were gross residual @entity1 (HR 7.96, 95% CI 2.54-24.97, P < 0. 001), age > or = 65 years (HR 6.22, 95% CI 2.05-18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95% CI 0.07-0.76, P = 0.016). We conclude that in @entity0 with @entity2 , complete resection of macroscopic @entity1 and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.

title: FIGO XXXX : resection of macroscopic @entity1 and other determinants of survival.

answer: @entity2


abstract: Activated macrophages express inducible isoforms of @entity3 synthase ( @entity9 ) and cyclooxygenase ( @entity7 ), and produce excessive amounts of @entity3 (NO) and @entity4 ( @entity4 ), which play key roles in the processes of @entity1 and @entity2 . The root of Paeonia lactiflora Pall., and the root cortex of Paeonia suffruticosa Andr., are important Chinese crude drugs used in many traditional prescriptions. @entity12 ( @entity13 ) is a major bioactive constituent of both crude drugs. @entity13 has been shown to possess potent anti-oxidant, anti-mutagenic, anti-proliferative and anti-invasive effects. In this study, we examined the inhibitory effects of @entity12 ( @entity13 ) isolated from the root of Paeonia lactiflora Pall. on the @entity7 and @entity9 activity in LPS-activated Raw 264.7 cells, @entity11 in HEL cells. To investigate the structure-activity relationships of gallate and @entity8 for the inhibition of @entity9 and @entity7 activity, we also examined @entity5 ( @entity6 ), @entity8 , and @entity14 . The results of the present study indicated that @entity13 , @entity6 , and @entity14 treatment except @entity8 significantly inhibited LPS-induced NO production in LPS-activated macrophages. All of the four compounds significantly inhibited @entity7 activity in LPS-activated macrophages. Among the four compounds examined, @entity13 revealed the most potent in both @entity9 (IC50 approximately 18 microg/mL) and @entity7 inhibitory activity ( @entity4 : IC50 approximately 8 microg/mL and @entity10 : IC50 approximately 12 microg/mL), respectively. Although further studies are needed to elucidate the molecular mechanisms and structure-activity relationship by which @entity13 exerts its inhibitory actions, our results suggest that @entity13 might be a candidate for developing anti-inflammatory and @entity0 chemopreventive agents.

title: Inhibition of inducible @entity3 synthase and cyclooxygenase-2 activity by XXXX in murine macrophage cells.

answer: @entity12


abstract: Activated macrophages express inducible isoforms of @entity3 synthase ( @entity9 ) and cyclooxygenase ( @entity7 ), and produce excessive amounts of @entity3 (NO) and @entity4 ( @entity4 ), which play key roles in the processes of @entity1 and @entity2 . The root of Paeonia lactiflora Pall., and the root cortex of Paeonia suffruticosa Andr., are important Chinese crude drugs used in many traditional prescriptions. @entity12 ( @entity13 ) is a major bioactive constituent of both crude drugs. @entity13 has been shown to possess potent anti-oxidant, anti-mutagenic, anti-proliferative and anti-invasive effects. In this study, we examined the inhibitory effects of @entity12 ( @entity13 ) isolated from the root of Paeonia lactiflora Pall. on the @entity7 and @entity9 activity in LPS-activated Raw 264.7 cells, @entity11 in HEL cells. To investigate the structure-activity relationships of gallate and @entity8 for the inhibition of @entity9 and @entity7 activity, we also examined @entity5 ( @entity6 ), @entity8 , and @entity14 . The results of the present study indicated that @entity13 , @entity6 , and @entity14 treatment except @entity8 significantly inhibited LPS-induced NO production in LPS-activated macrophages. All of the four compounds significantly inhibited @entity7 activity in LPS-activated macrophages. Among the four compounds examined, @entity13 revealed the most potent in both @entity9 (IC50 approximately 18 microg/mL) and @entity7 inhibitory activity ( @entity4 : IC50 approximately 8 microg/mL and @entity10 : IC50 approximately 12 microg/mL), respectively. Although further studies are needed to elucidate the molecular mechanisms and structure-activity relationship by which @entity13 exerts its inhibitory actions, our results suggest that @entity13 might be a candidate for developing anti-inflammatory and @entity0 chemopreventive agents.

title: Inhibition of inducible XXXX synthase and cyclooxygenase-2 activity by @entity12 in murine macrophage cells.

answer: @entity3


abstract: Problems have been raised by natural genetic diversity of @entity5 , the causal agent of @entity4 , and other protozoa in terms of both basic and applied science. @entity5 manifests a great diversity of medical and biological properties which could be the origin of clinical variability in the disease. We propose possible correlations between genetic distances, or phylogenetic divergence, and histopathological data. To ascertain this aspect, 15 cloned stocks pertaining to three major clones or genotypes (19, 20 and 39) were compared. Sets of 24 @entity1 infected with each stock were studied for histopathological lesions. Brain, heart, lung, liver, spleen, urinary bladder, bone marrow, @entity0 were extracted from each @entity1 . Qualitative and quantitative differences showed at histopathological examination. An important encephalic softening was found in brains of most @entity1 infected by genotype 20, corresponding to areas of @entity2 and liquified @entity3 . Other inflammatory tissue lesions in the histological sections of the three genotypes were similar. Skeletal muscle tropism was higher than cardiac tropism in all the studied genotypes. All three genotypes shared parasite presence in skeletal muscle. Differences related to cardiac tropism were important: in genotype 19, 50% of studied stocks presented @entity6 ; 20% in genotype 20 and 83% in genotype 39. Parasite presence in other tissues was scanty: in brain only in genotype 20 and in spleen and liver only in genotype 39. We found important histopathogenicity differences among the three studied genotypes, but they do not support the hypothesis of zymodeme pathogenic specificity due to the great diversity among stocks within each genotype.

title: Relationships between histopathological findings and phylogenetic divergence in XXXX .

answer: @entity5


abstract: BACKGROUND: @entity5 inhibits @entity2 and prolongs intestinal transit. This leads to increases in the proportion of @entity10 in, and @entity1 saturation of, gall bladder bile, factors that contribute to the pathogenesis of @entity5 induced @entity8 . AIMS: To see if an intestinal prokinetic, @entity7 , could overcome these adverse effects of @entity5 and if so, be considered as a candidate prophylactic drug for preventing @entity2 . METHODS: A randomised, double blind, placebo controlled, crossover design was used to examine the effects of @entity7 (10 mg four times daily) on @entity2 , mouth to caecum and large bowel transit times, and the proportions of @entity10 and other @entity6 , in fasting serum from: (i) control subjects (n=6), (ii) acromegalic @entity0 not treated with @entity5 (n=6), (iii) acromegalics on long term @entity5 (n=8), and (iv) @entity0 with @entity3 (n=8). RESULTS: @entity7 had no prokinetic effect on the gall bladder. In fact, it significantly increased both fasting and postprandial gall bladder volumes. However, it @entity4 to caecum (from 176 (13) to 113 (11) minutes; p<0.001) and large bowel (from 50 (3.0) to 31 (3.4) h; p<0.001) transit times. It also reduced the proportion of @entity10 in serum from 26 (2.3) to 15 (1.8)% (p<0.001), with a reciprocal increase in the proportion of @entity9 from 40 (3.5) to 51 (3.8)% (p<0.01). There were significant linear relationships between large bowel transit time and the proportions of @entity10 (r=0.81; p<0.001) and @entity9 (r=-0.53; p<0.001) in fasting serum. INTERPRETATION/SUMMARY: @entity7 failed to overcome the adverse effects of @entity5 on @entity2 but it countered @entity5 induced prolongation of small and large bowel transit. Therefore, if changes in intestinal transit contribute to the development of @entity5 induced @entity2 , enterokinetics such as @entity7 may prevent their formation.

title: Effects of @entity7 on XXXX , intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial.

answer: @entity2


abstract: BACKGROUND: @entity5 inhibits @entity2 and prolongs intestinal transit. This leads to increases in the proportion of @entity10 in, and @entity1 saturation of, gall bladder bile, factors that contribute to the pathogenesis of @entity5 induced @entity8 . AIMS: To see if an intestinal prokinetic, @entity7 , could overcome these adverse effects of @entity5 and if so, be considered as a candidate prophylactic drug for preventing @entity2 . METHODS: A randomised, double blind, placebo controlled, crossover design was used to examine the effects of @entity7 (10 mg four times daily) on @entity2 , mouth to caecum and large bowel transit times, and the proportions of @entity10 and other @entity6 , in fasting serum from: (i) control subjects (n=6), (ii) acromegalic @entity0 not treated with @entity5 (n=6), (iii) acromegalics on long term @entity5 (n=8), and (iv) @entity0 with @entity3 (n=8). RESULTS: @entity7 had no prokinetic effect on the gall bladder. In fact, it significantly increased both fasting and postprandial gall bladder volumes. However, it @entity4 to caecum (from 176 (13) to 113 (11) minutes; p<0.001) and large bowel (from 50 (3.0) to 31 (3.4) h; p<0.001) transit times. It also reduced the proportion of @entity10 in serum from 26 (2.3) to 15 (1.8)% (p<0.001), with a reciprocal increase in the proportion of @entity9 from 40 (3.5) to 51 (3.8)% (p<0.01). There were significant linear relationships between large bowel transit time and the proportions of @entity10 (r=0.81; p<0.001) and @entity9 (r=-0.53; p<0.001) in fasting serum. INTERPRETATION/SUMMARY: @entity7 failed to overcome the adverse effects of @entity5 on @entity2 but it countered @entity5 induced prolongation of small and large bowel transit. Therefore, if changes in intestinal transit contribute to the development of @entity5 induced @entity2 , enterokinetics such as @entity7 may prevent their formation.

title: Effects of XXXX on @entity2 , intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial.

answer: @entity7


abstract: OBJECT: The goal of this study was to investigate the risk of @entity2 in relation to exogenous and endogenous sex hormones. METHODS: The study @entity0 were female registered nurses from 11 US states who were between 30 and 55 years of age when they enrolled in the Nurses' Health Study cohort. These @entity0 completed biennial questionnaires between 1976 and 1996. All @entity0 were free from @entity1 and other major medical illness at the onset of the study. The primary endpoint was @entity2 as self-reported in biennial and supplemental questionnaires. During 1,213,522 @entity0 -years of follow-up review, 125 cases of @entity2 were confirmed. After adjusting for age and body mass index (BMI), compared with postmenopausal @entity0 who had never used postmenopausal hormones, the relative risk (RR) for premenopausal @entity0 was 2.48 (95% confidence interval [CI] 1.29-4.77; p = 0.01) and the RR for postmenopausal @entity0 who received hormone therapy was 1.86 (95% CI 1.07-3.24; p = 0.03). The authors found no excess risk associated with past hormone use. In models that additionally controlled for hormone use and menopausal status, the authors found that, compared with @entity0 whose menarche occurred before they were 12 years of age, the RR for @entity0 whose menarche occurred at ages 12 through 14 years was 1.29 (95% CI 0.86-1.92; p = 0.21) and the RR for @entity0 whose menarche occurred after age 14 years was 1.97 (95% CI 1.06-3.66; p = 0.03). The authors also observed a tendency, albeit nonsignificant, for increased risk of @entity2 in parous as opposed to nulliparous @entity0 (multivariate RR = 2.39, 95% CI 0.76-7.53; p = 0.14). A trend toward an increasing risk of @entity2 with increasing BMI was also noted (p for trend = 0.06). No association was found for past or current use of oral contraceptives. CONCLUSIONS: The risk for @entity2 was increased among @entity0 exposed to either endogenous or exogenous sex hormones. An unexpected relationship with increasing age at menarche was also noted; this remains unexplained.

title: Sex steroid hormone exposures and risk for XXXX .

answer: @entity2


abstract: This study compared characteristics related to sexual history, sexual activities, sexual functioning, and @entity3 tendencies associated with sexuality in 45 young adults with @entity1 treated with novel neuroleptics and in 61 young adults from a comparison group. A smaller proportion of young adults with @entity1 currently had a sexual partner or had ever engaged in sexual relations. They also had @entity3 often. Whether affected by @entity1 or not, a smaller proportion of @entity0 had ever masturbated, and a smaller proportion of @entity0 currently had a sexual partner. @entity0 masturbated less often, felt @entity3 , and desired sexual relations less often, compared with @entity0 . Proportionally more @entity0 with @entity1 treated with @entity5 or @entity4 than @entity0 in the comparison group had at least one @entity2 , lacked sexual desire, and reported problems with sexual arousal and ejaculation. @entity0 with @entity1 were more likely to report problems with sexual arousal and @entity6 , compared with @entity0 in the comparison group. Finally, young adults with @entity1 were more likely to develop negative @entity3 tendencies associated with sexuality than were young adults in the comparison group. Sexual problems are highly prevalent among young adults with @entity1 . Sexuality should occupy the space it deserves within psychosocial rehabilitation programs and the treatment of @entity1 .

title: Study of sexuality-related characteristics in young adults with XXXX treated with novel neuroleptics and in a comparison group of young adults.

answer: @entity1


abstract: OBJECTIVE: The aim of this study was to identify clinical and pathologic characteristics of @entity1 with uterine @entity4 (UPSC) who were all surgically managed at a single institution. The identified characteristics were then correlated with overall survival (OS). METHODS: One hundred twenty-nine @entity1 with FIGO stage I-IV UPSC who were surgically staged at the University of Texas M. D. Anderson @entity3 Center between 1989 and 2002 were identified. For each @entity1 , medical records and pathology reports were reviewed. The Kaplan-Meier method was used to generate OS data. Factors predictive of outcome were compared using the log-rank test and Cox regression analysis. RESULTS: There were 52 @entity1 with stage I disease, 5 with stage II, 41 with stage III, and 31 with stage IV. The median age at the time of diagnosis was 68 years (range, 44-93 years). A personal history of @entity0 was reported by 12.4% of the @entity1 , and a family history of @entity0 was reported by 16%. The 5-year OS among all @entity1 was 45.9%. Among the stage I @entity1 (IA, n = 19; IB, n = 26; and IC, n = 7), the 5-year OS was 62.9% (IA, 81.5%; IB, 58.6%; and IC, 34.3%). The 5-year OS for @entity1 with stage III and IV disease was 37.3 and 19.9%, respectively. Pathologic features predictive of OS included lymph node status (P </= 0.01), lymph vascular invasion (P </= 0.05), and depth of uterine invasion (P </= 0.05). Among @entity1 with no uterine invasion (n = 32), surgical staging revealed that 37% had stage III or IV disease. Among stage III @entity1 , those who received chemotherapy had a longer OS than those who did not receive chemotherapy (P = 0.03). CONCLUSION: In this population of nonselected @entity1 with UPSC, approximately 20% had a personal or family history of @entity0 . Stage, lymph node status, lymph vascular invasion, and depth of @entity2 were all risk factors for a worse prognosis. Traditional risk factors, however, did not predict the presence or the absence of @entity2 . Among @entity1 with noninvasive uterine disease, there was a high proportion with abdominal @entity2 . Therefore, complete surgical staging of these @entity1 is vital in determining their prognosis.

title: Uterine XXXX (UPSC): a single institution review of 129 cases.

answer: @entity4


abstract: BACKGROUND: The hand-carried cardiac ultrasound (HCU) device is a recently introduced imaging device, which may be potentially useful in the primary care setting. AIM: To test the screening potential of a HCU for the detection of left ventricular (LV) dysfunction by evaluating LV ejection fraction (LVEF) and inferior vena cava (IVC) collapse. Standard echocardiographic @entity1 ( @entity1 ) and plasma @entity3 ( @entity3 ) measurements were used as a reference. METHODS: Eighty-eight consecutive @entity0 (56 male, aged 59+/-12 years) with suspected @entity2 were enrolled in the study. The HCU-LVEF was visually estimated and the @entity1 -LVEF was derived by the Simpson's biplane method. A LVEF <40% represented @entity2 . An IVC collapse of <50% and @entity3 levels > or =15 pmol/l were considered abnormal. The correlation of HCU-LVEF, HCU-IVC and @entity3 to the @entity1 -LVEF and @entity1 -IVC was analysed independently using 2x2 tables. RESULTS: Six @entity0 were excluded because of poor echo images. 19/82 @entity0 had @entity2 . The HCU and @entity3 could identify 17 and 18 out of these 19 @entity0 , respectively. The agreement for LVEF and IVC collapse between @entity1 and HCU was 96% for both parameters. The sensitivity of IVC collapse, HCU-LVEF and @entity3 in identifying @entity0 with @entity2 was 26, 89 and 94%, respectively. CONCLUSION: A HCU device can reliably be used as a screening tool for @entity2 .

title: Screening for XXXX using a hand-carried cardiac ultrasound device.

answer: @entity2


abstract: OBJECTIVE: Sinus venosus type @entity1 (SVASD) differ from the secundum @entity1 by its location and high incidence of combination with other @entity3 , which inherently increases the risk of @entity2 . Right atriotomy is the most preferred approach for repairing the SVASD. @entity6 or other rhythm disturbances can be observed. We compared the @entity2 between lateral cavatomy and right atriotomy in @entity0 who had SVASD. METHODS: Twenty-seven @entity0 who had SVASD (of 384 total ASDs) associated with partial @entity4 (PAPVC) underwent surgical repair during the period of January 1992 - December 2001 in G  lhane Military Medical Academy. Sinus venosus type @entity1 was repaired through right atrial incision by routine bi-caval cannulation in 14 @entity0 (Group 1) and repaired through lateral caval incision by direct caval cannulation in 13 @entity0 (Group 2). Lateral cavatomy was closed by pericardial patch in Group 2. We analyzed the relationship between incidence of rhythm disturbances and the technique in @entity0 who had SVASD with or without partial @entity4 prospectively. RESULTS: All @entity0 had a classical superior SVASD intraoperatively. Persistent @entity8 (PLSVC) was observed in 5 @entity0 (Group 1=3 @entity0 , Group 2=2 @entity0 ). Postoperative mortality was seen in one @entity0 in Group 1 due to @entity7 . In Group 1, one @entity0 underwent re-operation for upper and middle lobectomy of the right lung. Ambulatory Holter monitorizations were done in all @entity0 per 3 months periodically. In Group 1 @entity6 was observed in 4 @entity0 and @entity5 was observed in 2 @entity0 , while in Group 2 only one @entity0 had @entity5 during follow-up period (p=0.037). CONCLUSION: Repair of SVASD in adult @entity0 is associated with low operative mortality and morbidity. The closure of the defect by pericardial patch is the most preferred technique but obstruction of caval veins can be seen. We suggest that posterior cavatomy can be preferred to atriotomy because of low incidence of @entity6 and pulmonary or caval obstruction.

title: [The relationship between rhythm disturbances and incisions in adult sinus venosus XXXX ].

answer: @entity1


abstract: PURPOSE: To determine the prevalence and characteristics of @entity1 ( @entity1 ) in @entity0 with @entity6 ( @entity6 ) according to subgroup analysis of symptoms. MATERIALS AND METHODS: We prospectively enrolled subjects with @entity6 (n=86) who were scheduled to undergo spinal surgery. The @entity0 were divided into two groups according to a chief complaint of @entity2 or @entity4 . We measured @entity0 's @entity2 score using the @entity3 ( @entity3 ), @entity5 ( @entity5 ) and Leads Assessment of Neuropathic Symptoms and Signs (LANSS). According to LANSS value, the prevalence of @entity1 component @entity2 in @entity0 with @entity6 was assessed. Statistical analysis was performed to find the relationship between LANSS scores and the other scores. RESULTS: From our sample of 86 @entity0 , 31 (36.0%) had a @entity1 component, with 24 (63.4%) in the @entity2 group having @entity1 . However, only seven @entity0 (15.6%) in the @entity4 group had @entity1 . The LANSS @entity2 score was not significantly correlated with @entity3 scores for back @entity2 , but did correlate with @entity3 scores for @entity2 (R=0.73, p<0.001) and with @entity5 back @entity2 scores (R=0.54, p<0.01). CONCLUSION: One-third of the @entity0 with @entity6 had a @entity1 component. The presence of @entity2 correlated strongly with @entity1 . The severity of @entity2 and @entity5 score were also closely related to a @entity1 component. This data may prove useful to understanding the @entity2 characteristics of @entity6 and in better designing clinical trials for @entity1 treatment in @entity0 with @entity6 .

title: XXXX Components in @entity0 with @entity6 .

answer: @entity1


abstract: PURPOSE: To determine the prevalence and characteristics of @entity1 ( @entity1 ) in @entity0 with @entity6 ( @entity6 ) according to subgroup analysis of symptoms. MATERIALS AND METHODS: We prospectively enrolled subjects with @entity6 (n=86) who were scheduled to undergo spinal surgery. The @entity0 were divided into two groups according to a chief complaint of @entity2 or @entity4 . We measured @entity0 's @entity2 score using the @entity3 ( @entity3 ), @entity5 ( @entity5 ) and Leads Assessment of Neuropathic Symptoms and Signs (LANSS). According to LANSS value, the prevalence of @entity1 component @entity2 in @entity0 with @entity6 was assessed. Statistical analysis was performed to find the relationship between LANSS scores and the other scores. RESULTS: From our sample of 86 @entity0 , 31 (36.0%) had a @entity1 component, with 24 (63.4%) in the @entity2 group having @entity1 . However, only seven @entity0 (15.6%) in the @entity4 group had @entity1 . The LANSS @entity2 score was not significantly correlated with @entity3 scores for back @entity2 , but did correlate with @entity3 scores for @entity2 (R=0.73, p<0.001) and with @entity5 back @entity2 scores (R=0.54, p<0.01). CONCLUSION: One-third of the @entity0 with @entity6 had a @entity1 component. The presence of @entity2 correlated strongly with @entity1 . The severity of @entity2 and @entity5 score were also closely related to a @entity1 component. This data may prove useful to understanding the @entity2 characteristics of @entity6 and in better designing clinical trials for @entity1 treatment in @entity0 with @entity6 .

title: @entity1 Components in @entity0 with XXXX .

answer: @entity6


abstract: PURPOSE: To determine the prevalence and characteristics of @entity1 ( @entity1 ) in @entity0 with @entity6 ( @entity6 ) according to subgroup analysis of symptoms. MATERIALS AND METHODS: We prospectively enrolled subjects with @entity6 (n=86) who were scheduled to undergo spinal surgery. The @entity0 were divided into two groups according to a chief complaint of @entity2 or @entity4 . We measured @entity0 's @entity2 score using the @entity3 ( @entity3 ), @entity5 ( @entity5 ) and Leads Assessment of Neuropathic Symptoms and Signs (LANSS). According to LANSS value, the prevalence of @entity1 component @entity2 in @entity0 with @entity6 was assessed. Statistical analysis was performed to find the relationship between LANSS scores and the other scores. RESULTS: From our sample of 86 @entity0 , 31 (36.0%) had a @entity1 component, with 24 (63.4%) in the @entity2 group having @entity1 . However, only seven @entity0 (15.6%) in the @entity4 group had @entity1 . The LANSS @entity2 score was not significantly correlated with @entity3 scores for back @entity2 , but did correlate with @entity3 scores for @entity2 (R=0.73, p<0.001) and with @entity5 back @entity2 scores (R=0.54, p<0.01). CONCLUSION: One-third of the @entity0 with @entity6 had a @entity1 component. The presence of @entity2 correlated strongly with @entity1 . The severity of @entity2 and @entity5 score were also closely related to a @entity1 component. This data may prove useful to understanding the @entity2 characteristics of @entity6 and in better designing clinical trials for @entity1 treatment in @entity0 with @entity6 .

title: @entity1 Components in XXXX with @entity6 .

answer: @entity0


abstract: @entity3 ( @entity3 ) involves multisystem @entity8 of unknown origin. Ocular manifestations of @entity3 mostly include bilateral @entity12 and @entity11 , which are very challenging to treat. Interferon alfa-2a (IFN) has been recently introduced for treating refractory Beh  et @entity10 , mainly in Germany and @entity6 . Nonetheless, there is so far no consensus about the ideal treatment regimen of IFN for Beh  et @entity10 . We report our experience of IFN treatment in five Korean @entity3 @entity0 with refractory @entity10 . All @entity0 @entity13 ; one @entity0 had a positive pathergy test and 2 showed the presence of HLA-B51. Immunosuppressive agents used prior to IFN treatment included @entity4 and @entity9 . The IFN treatment was commenced with a dose of 6-9 MIU/day for 7 days, adjusted according to individual ocular manifestations, tapered down to 3 MIU three times in a week, and then discontinued. All @entity0 showed positive response to IFN treatment; 50% of them showed complete response without additional major @entity1 during the follow-up period. @entity2 also improved after IFN treatment in most cases. After treatment, the relapse rate and the required dose of oral @entity5 were decreased in most cases, showing a significant @entity7 -sparing effect. However, the visual acuity was not improved in most cases due to irreversible macular sequelae. Despite the small sample size of this study, we suggest that, in Korean @entity0 , IFN is an effective treatment modality for @entity3 @entity10 as was observed in German and Turkish @entity0 .

title: Clinical Experience of Interferon Alfa-2a Treatment for XXXX in Beh  et's Disease.

answer: @entity10


abstract: OBJECTIVE: Pediatric radiotherapy is a day care procedure. In @entity0 , anaesthesia is necessary to prevent movement during the therapy. Traditionally intramuscular @entity9 is used for these procedure because of its inherent safety in a @entity0 who used to be left alone in the cobalt room. METHODS: This study was designed to explore the efficacy of @entity7 and @entity9 in pediatric radiotherapy in nineteen @entity0 . The inclusion criteria was a @entity0 fasting for six hours with no fever or URTI in the past week. A @entity0 coming to the radiotherapy (RT) unit without an intravenous cannula was given intramuscular @entity9 10 mg/kg and taken for the procedure. Before the @entity0 recovered from anaesthesia an intravenous cannula, 20-22G, Vasofix was inserted for subsequent sittings of RT. The @entity0 coming with an intravenous cannula was given @entity7 2.5 mg/kg with @entity8 (0.1 mg/kg) without @entity6 . The parameters recorded were pulse rate, @entity1 saturation and respiratory rate-baseline to every 30 seconds till five minutes. Onset time, recovery time, oral feeding time and any untoward effects like @entity2 , @entity3 , nystagmus were also noted. RESULT: The drug was graded on a scale of 0-10 according to parental acceptability where 0 is the worst and 10 is the best acceptability. The mean (+/-SD) of all the measured parameters were calculated and compared between the two groups. CONCLUSION: @entity7 was associated with faster onset, better recovery, early oral feeding time, no @entity2 and @entity3 and better parental acceptability. There was no @entity4 , @entity5 and @entity1 saturation at 60 seconds, which was between 94-95%, was easily treatable with supplementation of @entity1 by face mask.

title: XXXX for pediatric radiotherapy.

answer: @entity7


abstract: The report evaluates surgical drainage (SD) as a primary treatment of @entity3 ( @entity3 ). Seventy-two @entity0 , who underwent SD for @entity3 at B P Koirala Institute of Health Sciences, Dharan, Nepal were studied. SD was performed through a lower abdominal, extra peritoneel, muscle splitting incision. Ultrasonography was used to diagnose the abscess in 53/54 @entity0 (98%). @entity2 was the most frequent organism grown in 45/65 @entity0 (69%). The mean duration of drainage was 3.2 +/- 1.4 days (range, 1-7 days). The treatment was successful in resolving the abscesses in all @entity0 . The mean hospital stay was 9.0 +/- 5.4 days (range, 3-40 days). Two @entity0 (2.8%) developed a recurrence, 10 months and 1 year after the operation, respectively. Another @entity0 developed an incisional @entity1 . There were no deaths. The average cost of treatment to the @entity0 was approximately Nepali rupees 2800 (US  40). Surgical drainage appears to be a cost-effective and safe treatment for @entity3 .

title: Surgical drainage of XXXX --safe and cost-effective treatment.

answer: @entity3


abstract: Purpose. @entity3 ( @entity3 ) is known to be a significant but frequently overlooked complication after the use of neuromuscular blocking agents (NMBA). Aim of this prospective audit was to investigate the incidence and severity of @entity3 at our Australian tertiary pediatric center. Methods. All @entity0 receiving NMBA during anesthesia were included over a 5-week period at the end of 2011 (Mondays to Fridays; 8   a.m.-6   p.m.). At the end of surgery, directly prior to tracheal extubation, the @entity2 ( @entity2 ) ratio was assessed quantitatively. Data related to @entity0 postoperative outcome was collected in the postoperative acute care unit. Results. Data of 64 @entity0 were analyzed. @entity1 was given in 34 cases and @entity4 in 1 @entity0 . The incidence of @entity3 was 28.1% overall (without reversal: 19.4%; after @entity1 : 37.5%; n.s.). Severe @entity3 ( @entity2 ratio < 0.7) was found in 6.5% after both no reversal and @entity1 , respectively. Complications in the postoperative acute care unit were infrequent, with no differences between reversal and no reversal groups. Conclusions. In this audit, @entity3 was frequently observed, particularly in cases where @entity0 were reversed with @entity1 . These findings underline the well-known problems associated with the use of NMBA that are not fully reversed.

title: Postoperative Residual Neuromuscular Paralysis at an Australian Tertiary XXXX 's Hospital.

answer: @entity0


abstract: BACKGROUND: @entity7 and beta-amyloid ( @entity5 ) are proposed diagnostic biomarkers for @entity3 ( @entity3 ). Previous studies report their relationship to clinical diagnoses of @entity3 and other @entity4 . To understand their value as predictors of disease-specific pathology, levels determined during life must be correlated with definitive diagnoses in mixed @entity4 groups and cognitively normal subjects. OBJECTIVES: To correlate antemortem cerebrospinal fluid (CSF) tau and @entity5 levels with definitive @entity4 diagnosis in a diverse group of @entity0 ; to calculate statistics for CSF tau and @entity5 . DESIGN: Prospective study. SETTING: Ten clinics experienced in the diagnosis of @entity2 . @entity0 One hundred six @entity0 with @entity4 and 4 cognitively normal subjects with a definitive diagnosis, and 69 clinically diagnosed cognitively normal subjects. MAIN OUTCOME MEASURES: Correlation of CSF tau and @entity5 with final diagnosis. RESULTS: Mean tau level was 612 pg/mL for the 74 @entity0 with @entity3 , 272 pg/mL for 10 @entity0 with frontal @entity4 , 282 pg/mL for 3 @entity0 with @entity4 with @entity6 , and 140 pg/mL for 73 cognitively normal control subjects. Tau was less than 334 pg/mL for 20 @entity0 with @entity3 . Abeta42 was reduced in @entity0 with @entity3 (61 fmol/mL) compared with @entity0 with frontal @entity4 (133 fmol/mL) and control subjects (109 fmol/mL), but not compared with @entity0 with @entity4 with @entity6 (14 fmol/mL) or prion disease (60 fmol/mL). CONCLUSIONS: Elevated CSF tau levels are associated with @entity3 pathology and can help discriminate @entity3 from other @entity1 . However, some @entity0 with @entity3 have a level less than the mean +/- 2 SDs of the cognitively normal cohort.

title: Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed XXXX diagnoses?

answer: @entity4


abstract: PURPOSE: We conducted our study to determine the pharmacokinetics (PK) and clinical efficacy of oral mesna in @entity0 receiving @entity3 for soft tissue @entity2 . EXPERIMENTAL DESIGN: Seventeen @entity0 were enrolled in a randomized prospective Phase I/II study. Seventeen @entity0 were exposed to study medication. @entity3 was given at a dose of 2 g/m2/day for 5 days on a 21-day cycle. Before the first cycle, all @entity0 were randomized onto a crossover design and received either the approved i.v. or i.v./oral mesna regimen, with crossover for the second cycle of chemotherapy. The i.v. mesna regimen consisted of dosings (20% @entity3 dose) at 0, 4, and 8 h. The i.v./oral arm consisted of an i.v. mesna dosing (20% @entity3 dose) at 0 h, followed by oral tablet dosing (40% @entity3 dose) at 2 and 6 h. In- @entity0 clinical monitoring and phlebotomy and urine sampling for mesna, dimesna, and @entity3 PK were performed on all chemotherapy days. RESULTS: Thirteen @entity0 were evaluable for PK and 17 for efficacy and @entity1 . No significant differences were detected in the plasma PK of the concomitantly infused @entity3 . Rates of @entity4 were similar across mesna schedules. Four of 10 evaluable @entity0 demonstrated objective response. CONCLUSION: On the basis of our study, an i.v./oral mesna regimen is at least as uroprotective as the approved i.v. regimen. The i.v./oral regimen will improve @entity0 tolerance and convenience, allow for a reduction in elective hospitalizations for @entity3 chemotherapy, reduce the potential morbidity associated with inpatient administration of chemotherapy, and likely result in decreased costs of care.

title: Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue @entity2 treated with high-dose XXXX .

answer: @entity3